Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Clinical trial NCT07100080 · RECRUITING
Trial details
- NCT number
- NCT07100080
- Sponsor
- Bristol-Myers Squibb
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-05
- Primary completion
- 2028-12-15
- Enrollment
- 500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.